Carlos A Sanchez-Catasus1,2,3, Nicolaas I Bohnen1,3,4,5, Nicholas D'Cruz6, Martijn L T M Müller7,3. 1. Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan. 2. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands. 3. Morris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, Michigan. 4. Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan. 5. Neurology Service and GRECC, Veterans Administration Ann Arbor Healthcare System, Ann Arbor, Michigan; and. 6. Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium. 7. Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan; mmuller@c-path.org.
Abstract
Previous studies of animal models of Parkinson disease (PD) suggest an imbalance between striatal acetylcholine and dopamine, although other studies have questioned this. To our knowledge, there are no previous in vivo neuroimaging studies examining striatal acetylcholine-dopamine imbalance in PD patients. Using cholinergic and dopaminergic PET (18F-fluoroethoxybenzovesamicol [18F-FEOBV] and 11C-dihydrotetrabenazine [11C-DTBZ], respectively) and correlational tractography, our aim was to investigate the acetylcholine-dopamine interaction at 2 levels of dopaminergic loss in PD subjects: integrity loss of the nigrostriatal dopaminergic white matter tract and loss at the presynaptic-terminal level. Methods: The study involved 45 subjects with mild to moderate PD (36 men, 9 women; mean age, 66.3 ± 6.3 y, disease duration, 5.8 ± 3.6 y; Hoehn and Yahr stage, 2.2 ± 0.6) and 15 control subjects (9 men, 6 women; mean age, 69.1 ± 8.6 y). PET imaging was performed using standard protocols. We first estimated the integrity of the dopaminergic nigrostriatal white matter tracts in PD subjects by incorporating molecular information from striatal 11C-DTBZ PET into the fiber tracking process using correlational tractography (based on quantitative anisotropy [QA], a measure of tract integrity). Subsequently, we used voxel-based correlation to test the association of the mean QA of the nigrostriatal tract of each cerebral hemisphere with the striatal 18F-FEOBV distribution volume ratio (DVR) in PD subjects. The same analysis was performed for 11C-DTBZ DVR in 12 striatal subregions (presynaptic-terminal level). Results: Unlike 11C-DTBZ DVR in striatal subregions, the mean QA of the nigrostriatal tract of the most affected hemisphere showed a negative correlation with a striatal cluster of 18F-FEOBV DVR in PD subjects (corrected P = 0.039). We also found that the mean 18F-FEOBV DVR within this cluster was higher in the PD group than in the control group (P = 0.01). Cross-validation analyses confirmed these findings. We also found an increase in bradykinesia ratings associated with increased acetylcholine-dopamine imbalance in the most affected hemisphere (r = 0.41, P = 0.006). Conclusion: Our results provide evidence for the existence of striatal acetylcholine-dopamine imbalance in early PD and may provide an avenue for testing in vivo effects of therapeutic strategies aimed at restoring striatal acetylcholine-dopamine balance in PD.
Previous studies of animal models of Parkinson disease (PD) suggest an imbalance between striatal acetylcholine and dopamine, although other studies have questioned this. To our knowledge, there are no previous in vivo neuroimaging studies examining striatal acetylcholine-dopamine imbalance in PD patients. Using cholinergic and dopaminergic PET (18F-fluoroethoxybenzovesamicol [18F-FEOBV] and 11C-dihydrotetrabenazine [11C-DTBZ], respectively) and correlational tractography, our aim was to investigate the acetylcholine-dopamine interaction at 2 levels of dopaminergic loss in PD subjects: integrity loss of the nigrostriatal dopaminergic white matter tract and loss at the presynaptic-terminal level. Methods: The study involved 45 subjects with mild to moderate PD (36 men, 9 women; mean age, 66.3 ± 6.3 y, disease duration, 5.8 ± 3.6 y; Hoehn and Yahr stage, 2.2 ± 0.6) and 15 control subjects (9 men, 6 women; mean age, 69.1 ± 8.6 y). PET imaging was performed using standard protocols. We first estimated the integrity of the dopaminergic nigrostriatal white matter tracts in PD subjects by incorporating molecular information from striatal 11C-DTBZ PET into the fiber tracking process using correlational tractography (based on quantitative anisotropy [QA], a measure of tract integrity). Subsequently, we used voxel-based correlation to test the association of the mean QA of the nigrostriatal tract of each cerebral hemisphere with the striatal 18F-FEOBV distribution volume ratio (DVR) in PD subjects. The same analysis was performed for 11C-DTBZ DVR in 12 striatal subregions (presynaptic-terminal level). Results: Unlike 11C-DTBZ DVR in striatal subregions, the mean QA of the nigrostriatal tract of the most affected hemisphere showed a negative correlation with a striatal cluster of 18F-FEOBV DVR in PD subjects (corrected P = 0.039). We also found that the mean 18F-FEOBV DVR within this cluster was higher in the PD group than in the control group (P = 0.01). Cross-validation analyses confirmed these findings. We also found an increase in bradykinesia ratings associated with increased acetylcholine-dopamine imbalance in the most affected hemisphere (r = 0.41, P = 0.006). Conclusion: Our results provide evidence for the existence of striatal acetylcholine-dopamine imbalance in early PD and may provide an avenue for testing in vivo effects of therapeutic strategies aimed at restoring striatal acetylcholine-dopamine balance in PD.
Authors: Jonathan W McKinley; Ziqing Shi; Ivana Kawikova; Matthew Hur; Ian J Bamford; Suma Priya Sudarsana Devi; Annie Vahedipour; Martin Darvas; Nigel S Bamford Journal: Neuron Date: 2019-07-16 Impact factor: 17.173
Authors: Xia Shao; Raphaël Hoareau; Brian G Hockley; Louis J M Tluczek; Bradford D Henderson; Henry C Padgett; Peter J H Scott Journal: J Labelled Comp Radiopharm Date: 2011-05-30 Impact factor: 1.921
Authors: Shu-Ying Liu; Daryl J Wile; Jessie Fanglu Fu; Jason Valerio; Elham Shahinfard; Siobhan McCormick; Rostom Mabrouk; Nasim Vafai; Jess McKenzie; Nicole Neilson; Alexandra Perez-Soriano; Julieta E Arena; Mariya Cherkasova; Piu Chan; Jing Zhang; Cyrus P Zabetian; Jan O Aasly; Zbigniew K Wszolek; Martin J McKeown; Michael J Adam; Thomas J Ruth; Michael Schulzer; Vesna Sossi; A Jon Stoessl Journal: Lancet Neurol Date: 2018-02-16 Impact factor: 44.182
Authors: M Herrera-Marschitz; M Goiny; H Utsumi; S Ferre; L Håkansson; A Nordberg; U Ungerstedt Journal: Neurosci Lett Date: 1990-03-02 Impact factor: 3.046
Authors: Fang-Cheng Yeh; Jean M Vettel; Aarti Singh; Barnabas Poczos; Scott T Grafton; Kirk I Erickson; Wen-Yih I Tseng; Timothy D Verstynen Journal: PLoS Comput Biol Date: 2016-11-15 Impact factor: 4.475
Authors: Nazanin Baradaran; Sun Nee Tan; Aiping Liu; Ahmad Ashoori; Samantha J Palmer; Z Jane Wang; Meeko M K Oishi; Martin J McKeown Journal: Front Neurol Date: 2013-06-05 Impact factor: 4.003
Authors: Siamak Nejad-Davarani; Robert A Koeppe; Roger L Albin; Kirk A Frey; Martijn L T M Müller; Nicolaas I Bohnen Journal: Mol Psychiatry Date: 2018-08-06 Impact factor: 15.992
Authors: Nicolaas I Bohnen; Alison J Yarnall; Rimona S Weil; Elena Moro; Mark S Moehle; Per Borghammer; Marc-André Bedard; Roger L Albin Journal: Lancet Neurol Date: 2022-02-04 Impact factor: 44.182